亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa

医学 大疱性表皮松解症 皮肤病科 人口 疾病 儿科 内科学 环境卫生
作者
Adam Raymakers,Aaron S. Kesselheim,Arash Mostaghimi,William B. Feldman
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:160 (3): 297-297 被引量:3
标识
DOI:10.1001/jamadermatol.2023.5857
摘要

Importance New gene therapies can offer substantial benefits to patients, particularly those with rare diseases who have few therapeutic options. In May 2023, the US Food and Drug Administration (FDA) approved the first topical gene therapy, beremagene geperpavec (B-VEC), for treating both autosomal recessive and autosomal dominant dystrophic epidermolysis bullosa (DEB). However, FDA approval was based on limited data in patients with autosomal dominant disease, even though they comprise approximately 50% of all DEB cases. Objective To estimate projected spending in the US on B-VEC therapy for treating autosomal recessive and autosomal dominant DEB. Design, Setting, and Participants This economic evaluation used data from the National Epidermolysis Bullosa Registry to estimate the current population of US patients with autosomal dominant and autosomal recessive DEB, with the aim of estimating US spending on B-VEC therapy from an all-payers perspective during 1- and 3-year periods after FDA approval. A base-case cost of $300 000 per patient per year was assumed based on a report from the manufacturer (Krystal Biotech). Exposure Treatment with B-VEC. Main Outcomes and Measures Estimated overall spending on B-VEC in the first year and over a 3-year period after FDA approval. Several prespecified sensitivity analyses with different assumptions about the eligible patient population and the cost of therapy were performed, and lifetime total costs of treatment per patient were estimated. Results The estimated number of US patients with DEB who were eligible for treatment with B-VEC in the first year after FDA approval was 894. The estimated total expenditure for B-VEC therapy was $268 million (range, $179 million-$357 million). Over a 3-year period, estimated spending was $805 million (range, $537 million-$1.1 billion). Estimated lifetime total costs per patient were $15 million (range, $10 million-$20 million) per patient with autosomal recessive DEB and $17 million (range, $11 million-$22 million) for patients with autosomal dominant DEB. Conclusions and Relevance Results of this economic evaluation suggest that the FDA’s broad indication for the use of B-VEC in treating both autosomal recessive and autosomal dominant DEB will have significant implications for payers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
h3m完成签到 ,获得积分10
3秒前
9464完成签到 ,获得积分10
8秒前
12秒前
汉堡包应助谷粱夏山采纳,获得10
16秒前
沉默白猫完成签到 ,获得积分10
23秒前
隐形曼青应助Tianqi采纳,获得10
32秒前
44秒前
hehehe完成签到,获得积分10
46秒前
Billy应助GeoEye采纳,获得30
51秒前
hehehe发布了新的文献求助10
51秒前
善学以致用应助wyq采纳,获得10
1分钟前
爆米花应助科研通管家采纳,获得200
1分钟前
yeyi9851应助科研通管家采纳,获得10
1分钟前
Hayat应助科研通管家采纳,获得10
1分钟前
CC2333完成签到 ,获得积分10
1分钟前
libobobo完成签到 ,获得积分10
1分钟前
1分钟前
dhyzf1214完成签到,获得积分10
1分钟前
忧郁小鸽子完成签到,获得积分10
1分钟前
科研狗发布了新的文献求助10
1分钟前
可爱的函函应助Huang采纳,获得30
1分钟前
李健的小迷弟应助科研狗采纳,获得10
1分钟前
铮铮铁骨发布了新的文献求助10
1分钟前
嗯哼应助醉酒笑红尘采纳,获得10
2分钟前
2分钟前
wangbq完成签到 ,获得积分10
2分钟前
Huang发布了新的文献求助30
2分钟前
2分钟前
Huang完成签到,获得积分10
2分钟前
wyq发布了新的文献求助10
2分钟前
2分钟前
嗯哼应助wyq采纳,获得10
2分钟前
0201完成签到 ,获得积分10
2分钟前
薯条狂热爱好者完成签到 ,获得积分10
2分钟前
风趣的梦露完成签到,获得积分20
2分钟前
2分钟前
123y完成签到,获得积分10
2分钟前
longer发布了新的文献求助10
2分钟前
3分钟前
3分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
New China Forges Ahead: Important Documents of the Third Session of the First National Committee of the Chinese People's Political Consultative Conference 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056430
求助须知:如何正确求助?哪些是违规求助? 2713056
关于积分的说明 7434409
捐赠科研通 2358078
什么是DOI,文献DOI怎么找? 1249228
科研通“疑难数据库(出版商)”最低求助积分说明 606981
版权声明 596195